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Alterations in synapse number and morphology are associated with devastating psychiatric and
neurologic disorders. In this issue of Cell, Margolis et al. (2010) show that the RhoA-guanine
exchange factor (GEF) Ephexin5 limits the numbers of excitatory synapses that neurons receive,
thus identifying a new mechanism controlling synaptogenesis.The anatomical and functional basis for
communication between neurons is the
synapse, a specialized site of cell-cell
contact. Synapses consist of a presyn-
aptic terminal, with neurotransmitter-filled
vesicles, and a postsynaptic terminal con-
taining receptors. Work during the past 10
years has demonstrated a significant role
for a number of trans-synaptic adhesion
proteins in the process of synapse forma-
tion (Dalva et al., 2007). Prominent among
these are the EphB family of receptor tyro-
sine kinases. EphBs are required for the
formation of normal numbers of excitatory
synapses, acting throughcontrol of filopo-
dia motility to mediate the formation of
these connections during specific devel-
opmental times (Dalva et al., 2007; Kayser
et al., 2008). Although anumber of positive
regulators of synapse formation have
been described, we know less about the
factors that prevent neurons from gener-
ating too many contacts. In this issue of
Cell, an elegant and comprehensive paper
by Margolis et al. (2010) shows that the
RhoA-guanine exchange factor (GEF)
Ephexin5 (also called Vsm-Rho-GEF
[Ogita et al., 2003]) limits the synaptogenic
activity of EphB2, restricting synapse
formation. EphB2, in turn, limits Ephexin5
activity by promoting its degradation by
the E3 ligase Ube3A, relieving the restric-
tions on synapse formation. Of note,
Ube3A is the gene that is defective in the
neurogenetic cognitive disorder known
as Angelman syndrome, which strikes
about one in 10,000 live births (Dan, 2009).
Only a small fraction of the contacts
between neuronal membranes yields
anatomically definable synaptic struc-
tures, suggesting that, in addition to
mechanisms that generate synapses,
neurons must have ways to restrict
synapse formation. Known negative regu-lators of synapse formation act through
a variety of mechanisms. For instance,
increased neuronal activity, acting
through the transcription factor MEF2
(Flavell et al., 2006), and restricted delivery
of presynaptic proteins to synaptic sites
(Patel and Shen, 2009) can each limit
synapse development. Margolis et al.
now show that the guanine exchange
factor Ephexin5 constrains synapse
formation by restricting a specific inducer
of synapse formation, EphB2 (Figure 1).
Ephexins are a family of five GEFs, of
which only Ephexin1 and Ephexin5 are
highly expressed in the brain (Sahin
et al., 2005). GEFs control GTPase activa-
tion by catalyzing the exchange of GDP
for GTP. When phosphorylated by
EphA4, Ephexin1 has potent RhoA-acti-
vating characteristics, making these
GEFs likely mediators of RhoA-depen-
dent reorganization of the actin cytoskel-
eton in the nervous system. Ephexin1
mediates ephrin-A-dependent growth
cone collapse, andmice lacking Ephexin1
have muscle weakness and impaired
synaptic transmission at the neuromus-
cular junction, likely due to malformation
of the active zone (Shamah et al., 2001;
Shi et al., 2010). However, the function
of Ephexin5 has remained obscure.
To identify candidate molecules that
might constrain the number of synapses
formed downstream of EphB2, perhaps
by inhibiting cell motility, Margolis and
colleagues first examine the pattern of
expression of a number of candidate
RhoA GEFs, finding that expression of
Ephexin5 matches the pattern of EphB
expression. Moreover, in a well-controlled
series of experiments, theauthors demon-
strate that, whereas Ephexin1 interacts
selectivelywithEphA4, Ephexin5 interacts
selectively with EphB2 in vitro and in vivo,Cell 143hasRhoAactivating ability that relies on its
Dbl-homology domain, and fails to acti-
vate either rac1 or CDC-42 GTPases.
The RhoA activity in Ephexin5 knockout
mice is reduced compared with controls,
suggesting that Ephexin5 is amajor deter-
minant of RhoA levels in the brain.
The authors then use a comprehensive
approach to examine the role of Ephexin5
in the control of synapse number. They
use shRNA to knock out Ephexin5 in
cultured neurons and also test synapse
formation in neurons produced from
Ephexin5 knockout mice. In both cases,
neurons lacking Ephexin5 generate more
excitatory synapses compared to
controls. In contrast, overexpression of
Ephexin5 results in a marked decrease
in the number of synapses. Importantly,
these effects depend on the guanine
nucleotide exchange activity of Ephexin5.
Then, in a clever series of experiments
using brain slices from a conditional
Ephexin5 knockout mouse, the authors
show that Ephexin5 activity also restricts
synapse formation in intact neuronal
circuits. Thus, the Ephexin5 GEF limits
the number of excitatory synapses that
neurons make in vitro and in vivo.
Margolis et al. next show that the
effects of Ephexin5 are due to a restric-
tion of EphB2 function during synapse
development. Of interest, although the
effects of Ephexin5 on synapse density
depend on EphB2 kinase activity,
EphB2 activation actually inactivates
Ephexin5 by phosphorylation of a specific
tyrosine residue, and the inactivation of
Ehpexin5 is required for EphB-depen-
dent synapse formation. These results
suggest a negative feedback loop,
whereby Ephexin5 negatively regulates
EphB2, which in turn inhibits Ephexin5
via phosphorylation., October 29, 2010 ª2010 Elsevier Inc. 341
Figure 1. Ephexin5 Represses Synapse Development
Margolis et al. (2010) show that the guanine exchange factor (GEF) Ephexin5 inhibits synapse formation by
activating RhoA prior to the activation of the EphB2 receptor by its ephrin-B ligands (left). Once engaged
by ligand, EphB2 promotes Ephexin5 phosphorylation, leading to its ubiquitination and degradation by the
E3 ubiquitin ligase Ube3A (center). EphB2 can then coordinate synapse maturation by interacting with
presynaptic ephrin-Bs, regulating the maturation of dendritic spines and recruiting glutamate receptors
(AMPA receptor and NMDA receptor) to the synapse (right).In conducting these experiments, the
authors note that the expression level of
Ephexin5 is reduced in the presence
of EphB2, raising the possibility that
Ephexin5 is regulated by proteasomal
degradation. In fact, the authors demon-
strate that proteasomal destabilization of
the Ephexin5 protein is tightly regulated
by EphB2 in vitro and in vivo. In cell lines,
the expression of EphB2 promotes
a decrease in Ephexin5 levels, and this
effect requires phosphorylation of
Ephexin5. Furthermore, a blockade of
the proteasome prevents EphB2-depen-
dent degradation of Ephexin5. In vivo,
Ephexin5 protein levels are high during
times of low synapse formation (P0-P3)
and low during periods of rapid synapse
addition (P7-P21). However, mRNA levels
of Ephexin5 remain constant throughout,
consistent with the idea that phosphoryla-
tion of Ephexin5 by EphB2 leads to
Ephexin5 degradation. Of interest,
previous reports indicate that EphB2
controls synapse formation via regulation
of filopodial motility during a similar period
of development, suggesting that changes
in Ephexin5 protein levels are the likely
mechanism in initiating or limiting these
events (Kayser et al., 2008). Finally, the
authors show that Ephexin5 is ubiquiti-
nated in brain lysates and that it interacts342 Cell 143, October 29, 2010 ª2010 Elseviwith the E3 ligase Ube3A, which is
required for Ephexin5 degradation.
The link toUbe3A is noteworthybecause
this E3 ligase is defective in 90% of Angel-
man syndrome cases (reviewed in Dan,
2009). In the current study, the authors
link Ephexin5 to the etiology of Angelman
syndrome using a mouse model of the
disease in which the maternal inherited
copy of Ube3A is deleted (Ube3Am/p+).
In brains of these mice, the levels of
Ephexin5 expression and the amount of
ubiquitinated Ephexin5 protein are in-
creased. Moreover, neurons cultured
from these mice are insensitive to ephrin-
B1 treatment. In these neurons, ephrin-B1
fails to induce reduced levels of Ephexin5
expression. These results lead the authors
to suggest that the cognitive defects in An-
gelman syndrome might result from
increased levels of Ephexin5 protein.
Margolis et al. have defined a mecha-
nism that restricts that activity of a specific
synaptogenic factor in vivo and in func-
tional neuronal circuits. EphB2 initiates
synapse development by interacting with
specific presynaptic ephrin-B proteins.
Ephexin5 suppresses this activity, and
EphB2 relieves this repression by phos-
phorylating and directing Ephexin5 for
degradation by the E3 ligase Ube3A
(Figure 1). These findings cement EphBser Inc.as a key regulator of excitatory synapse
development and suggest the interesting
possibility that other known synaptogenic
factors will have similarly selective restric-
tive mechanisms. How Ephexin5 acts
to restrict EphB2-dependent synapse
formation remains unknown, but con-
sidering that RhoA activation typically
suppresses cell motility, these findings
suggest that Ephexin5 might limit EphB2
function during synapse formation by
downregulating the motility of dendritic
filopodia that EphB2 has previously been
shown to mediate. The authors suggest
that this may be the case by indicating
that Ephexin5 may limit filopodial motility
in preliminary unpublished work. Beyond
its impact on understanding synapse
development, the study provides a tanta-
lizing and exciting potential mechanism
to explain the cognitive and behavioral
defects in patients with Angelman
syndrome.
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